StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Zevra Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $83.87M. For fiscal 2025 it was -$58.89M. The highest annual figure on record is $7.99M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$58.89M–
FY2024Dec 31, 2024-$80.61M–
FY2023Dec 31, 2023-$48.60M–
FY2022Dec 31, 2022-$41.62M-621.2%
FY2021Dec 31, 2021$7.99M–
FY2020Dec 31, 2020-$5.34M–
FY2019Dec 31, 2019-$20.03M–
FY2018Dec 31, 2018-$55.58M–
FY2017Dec 31, 2017-$33.03M–
FY2016Dec 31, 2016-$37.31M–
FY2015Dec 31, 2015-$22.73M–
FY2014Dec 31, 2014-$16.37M–
FY2013Dec 31, 2013-$4.65M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.14M–
Q1 FY2026Mar 31, 2026$52.51M–
Q4 FY2025Dec 31, 2025$9.68M–
Q3 FY2025Sep 30, 2025$4.54M–
Q2 FY2025Jun 30, 2025-$69.39M–
Q1 FY2025Mar 31, 2025-$3.71M–
Q4 FY2024Dec 31, 2024-$13.77M–
Q3 FY2024Sep 30, 2024-$25.69M–
Q2 FY2024Jun 30, 2024-$22.23M–
Q1 FY2024Mar 31, 2024-$18.92M–
Q4 FY2023Dec 31, 2023-$14.37M–
Q3 FY2023Sep 30, 2023-$15.30M–
Q2 FY2023Jun 30, 2023-$6.17M–
Q1 FY2023Mar 31, 2023-$12.75M–
Q4 FY2022Dec 31, 2022-$9.01M–
Q3 FY2022Sep 30, 2022-$6.23M–
Q2 FY2022Jun 30, 2022-$24.59M-516.9%
Q1 FY2022Mar 31, 2022-$1.79M-125.5%
Q4 FY2021Dec 31, 2021-$2.78M–
Q3 FY2021Sep 30, 2021-$2.16M–
Q2 FY2021Jun 30, 2021$5.90M+121.6%
Q1 FY2021Mar 31, 2021$7.02M–
Q4 FY2020Dec 31, 2020-$3.15M–
Q3 FY2020Sep 30, 2020-$1.15M-134.6%
Q2 FY2020Jun 30, 2020$2.66M–
Q1 FY2020Mar 31, 2020-$3.70M–
Q4 FY2019Dec 31, 2019-$4.34M–
Q3 FY2019Sep 30, 2019$3.31M–
Q2 FY2019Jun 30, 2019-$7.72M–
Q1 FY2019Mar 31, 2019-$11.29M–
Q4 FY2018Dec 31, 2018-$9.19M–
Q3 FY2018Sep 30, 2018-$17.88M–
Q2 FY2018Jun 30, 2018-$13.83M–
Q1 FY2018Mar 31, 2018-$14.69M–
Q4 FY2017Dec 31, 2017-$8.07M–
Q3 FY2017Sep 30, 2017-$9.53M–
Q2 FY2017Jun 30, 2017-$8.14M–
Q1 FY2017Mar 31, 2017-$7.30M–
Q4 FY2016Dec 31, 2016-$10.76M–
Q3 FY2016Sep 30, 2016-$10.36M–

More Zevra Therapeutics figures

See a number that looks wrong?